Evidence map›Paper›PMID 42472815›Full record

ArticleMolecular cancer2026

ADSL drives fumarate mediated scrib-rictor complex formation to promote metastasis dissemination in triple-negative breast cancer.

Yidan Fan, Xiaofang He, Wei Deng, Jianxiang Sun, Jinkun Qin, Yutian Zou, Xudong Zhu, Xiaoming Xie, Hailin Tang, Ping Yu and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yidan Fan *Department of Breast Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat- Sen University Cancer Center, 651 East Dongfeng Road, Guangzhou, Guangdong, 510060, China.
Xiaofang He *Department of Radiation Oncology, The First Affiliated Hospital of Sun Yat- sen University, Guangzhou, 510080, China.
Wei Deng *Department of Breast Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat- Sen University Cancer Center, 651 East Dongfeng Road, Guangzhou, Guangdong, 510060, China.
Jianxiang Sun *Department of Breast Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat- Sen University Cancer Center, 651 East Dongfeng Road, Guangzhou, Guangdong, 510060, China.
Jinkun QinDepartment of Breast Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat- Sen University Cancer Center, 651 East Dongfeng Road, Guangzhou, Guangdong, 510060, China.
Yutian ZouDepartment of Breast Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat- Sen University Cancer Center, 651 East Dongfeng Road, Guangzhou, Guangdong, 510060, China.
Xudong ZhuDepartment of General Surgery, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital &Institute, Shenyang, Liaoning, 110042, China.
Xiaoming XieDepartment of Breast Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat- Sen University Cancer Center, 651 East Dongfeng Road, Guangzhou, Guangdong, 510060, China.
Hailin TangDepartment of Breast Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat- Sen University Cancer Center, 651 East Dongfeng Road, Guangzhou, Guangdong, 510060, China.
Ping YuDepartment of Surgery and Anesthesiology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Dongfengdong Road 651, Guangzhou, 510060, China. yuping@sysucc.org.cn.
Weiyu BaoBreast Disease Diagnosis and Treatment Center, Sun Yat-sen University Cancer Center Gansu Hospital, Gansu Provincial Cancer Hospital, Gansu Provincial Academic Institute for medical research, NO.2 Xiaoxihu East Street, Lanzhou, Gansu, 730050, China. 16532794@qq.com.
Feng YeDepartment of Breast Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat- Sen University Cancer Center, 651 East Dongfeng Road, Guangzhou, Guangdong, 510060, China. yefeng@sysucc.org.cn.

Funding

National Natural Science Foundation of China 82303738Natural Science Foundation of Guangdong Province 2023A1515030040Natural Science Foundation of Guangdong Province 2024A1515012207Science and Technology Plan Projects of Gansu Province 25JRRA1295
6 · The paper itself

Abstract

backgroundTriple-negative breast cancer (TNBC) is characterized by aggressive metastatic behavior and limited therapeutic options. Although metabolic reprogramming is increasingly recognized as a hallmark of TNBC, the mechanisms by which specific metabolic enzymes and intermediates drive metastasis remain poorly defined.

methodsWe performed untargeted metabolomic profiling on TNBC tumors and matched normal tissues to identify dysregulated metabolic pathways. Functional assays, chemoproteomic succination profiling, molecular interaction analyses, and in vivo cancer metastasis models were used to define the mechanistic and biological consequences of altered metabolism. In vitro experiments validated the effects of N-acetylcysteine (NAC) in TNBC cell lines.

resultsMetabolomic analyses revealed aberrant activation of the alanine-aspartate-glutamate axis and upregulation of adenylosuccinate lyase (ADSL) in TNBC. ADSL promoted tumor cell proliferation and metastasis by generating fumarate, which accumulated primarily through covalent protein succination. Chemoproteomic profiling identified the cell polarity regulator SCRIB as a critical fumarate target. Fumarate-mediated succination of SCRIB impaired its membrane localization, promoted epithelial-mesenchymal transition, and facilitated aberrant interaction with the mTORC2 component RICTOR, leading to activation of AKT/mTOR signaling. Genetic disruption of SCRIB succination abrogated these effects. Importantly, pharmacological perturbation of fumarate using NAC reduced SCRIB succination and attenuated the malignant phenotypes of TNBC cells in vitro.

conclusionsThese findings identify an ADSL-fumarate-SCRIB signaling axis that links metabolic reprogramming to the loss of cell polarity and activation of pro-metastatic signaling in TNBC. Targeting fumarate-mediated protein succination represents a previously unrecognized and experimental vulnerability in TNBC.

Indexed as

Adenylosuccinate LyaseFumaratesMembrane ProteinsRapamycin-Insensitive Companion of mTOR ProteinTriple Negative Breast NeoplasmsTumor Suppressor ProteinsAnimalsCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMetabolic ReprogrammingMiceNeoplasm MetastasisSignal TransductionAdenylosuccinate LyaseFumaratesMembrane ProteinsRapamycin-Insensitive Companion of mTOR ProteinSCRIB protein, humanTumor Suppressor ProteinsAdenylosuccinate lyaseFumarateMetastasisSCRIBTriple-negative breast cancer

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.